Evidence map›Paper›PMID 41521552›Full record

ReviewHuman vaccines & immunotherapeutics2026

Valentina Caradonna, Agnes Hunyady, Usman Nakakana, Miren Iturriza, Francesca Micoli, Omar Rossi, Francesca Mancini

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Human vaccines & immunotherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Valentina CaradonnaDepartment of Medical Biotechnologies, University of Siena, Siena, Italy.
Agnes HunyadyGSK Global Health Vaccines R&D (GVGH), Siena, Italy.
Usman NakakanaGSK Global Health Vaccines R&D (GVGH), Siena, Italy.
Miren IturrizaGSK Global Health Vaccines R&D (GVGH), Siena, Italy.
Francesca MicoliGSK Global Health Vaccines R&D (GVGH), Siena, Italy.
Omar RossiGSK Global Health Vaccines R&D (GVGH), Siena, Italy.
Francesca ManciniGSK Global Health Vaccines R&D (GVGH), Siena, Italy.ORCID 0000-0003-2122-9480

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Shigellosis represents a major global health challenge, significantly contributing to mortality among children under five, particularly in sub-Saharan Africa and South Asia. Advances in molecular techniques have underscored the extensive global impact of

Indexed as

Cross ProtectionDysentery, BacillaryShigella flexneriShigella sonneiShigella VaccinesAfrica South of the SaharaAsia, SouthernCross ReactionsGlobal HealthHumansO AntigensSerogroupVaccine DevelopmentO AntigensShigella Vaccinescross-reactivityepidemiologyShigellavaccines

Identifiers

PMID41521552
PMCPMC12802990

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.